Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,501–1,600 of 4,275
Aging, cellular senescence and Parkinson's disease
Ma, Y., Erb, M. L., & Moore, D. J. (2025) · Journal of Parkinson's Disease · doi:10.1177/1877718x251316552 · Cited by 44
“12 Since then, the SASP has become a widely recognized phenomenon in the fi eld of cellular senescence and has been extensively studied for its roles in various biological processes.”
The senescent microenvironment promotes the emergence of heterogeneous cancer stem-like cells
Castro‐Vega, L. J., Jouravleva, K., Ortíz-Montero, P., Liu-Bordes, W.-Y., Galeano, J. L., Romero, M. L., Popova, T. G., Bacchetti, S., Vernot, J., & Londoño‐Vallejo, A. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv101 · Cited by 45
“SASP can also impact the differentiation status of tumor cells (15) and induce an epithelial-to-mesenchymal transition (EMT) (16).”
BackgroundThe role of vitamin D on redox regulation and cellular senescence
Sosa-Díaz, E., Cruz, E. Y. H., & Pedraza‐Chaverrí, J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.10.003 · Cited by 44
IFN-Aging: Coupling Aging With Interferon Response
Cao, W. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.870489 · Cited by 49
“At a late stage, senescent cells accumulate cytosolic DNA from activated LINE-1, a family of TEs, which activates the cGAS-STING innate signaling pathway to initiate IFN-I response as part of full SASP (Franceschi and Campisi 2014; De Cecco et al., 2019).”
BackgroundThe Achilles’ heel of cancer survivors: fundamentals of accelerated cellular senescence
Shafqat, S., Arana‐Chicas, E., Shafqat, A., & Hashmi, S. K. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158452 · Cited by 46
Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression
Kohli, J. S., Chen, G., Fitsiou, E., Doepner, M., Brandenburg, S. M., Faller, W. J., Ridky, T. W., & Demaria, M. (2022) · Nature Communications · doi:10.1038/s41467-022-35657-9 · Cited by 46
“Besides p16 expression, senescent cells also develop a complex senescence-associated secretory phenotype (SASP) that entails the expression and secretion of numerous pro-in fl ammatory factors 9,10 .”
Activatable senoprobes and senolytics: Novel strategies to detect and target senescent cells
Morsli, S., Doherty, G. J., & Muñoz-Espín, D. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111618 · Cited by 42
Crochemore, C., Molina, C. F., Montagne, B., Salles, A., & Ricchetti, M. (2019) · Nature Communications · doi:10.1038/s41467-019-13314-y · Cited by 47
Normal Aging and Its Role in Cancer Metastasis
Fane, M. E., & Weeraratna, A. T. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037341 · Cited by 45
“They secrete angiogenic factors such as VEGF to promote angiogenesis to allow efficient dissemination and nutrient supply, and a large number of growth factors (IGFBP, CSF) to reinforce an aggressive cancer phenotype.”
BackgroundInfluentialPini, M., Czibik, G., Sawaki, D., Mezdari, Z., Braud, L., Delmont, T., Mercedes, R., Martel, C., Buron, N., Marcelin, G., et al. (2021) · Aging Cell · doi:10.1111/acel.13421 · Cited by 43
“…that WAT can develop a senescence- associated secretory phenotype (SASP) that entails the release of various pro- inflammatory (Campisi, 2005; Coppe et al., 2008; MunozEspin & Serrano, 2014), but also profibrotic proteins (Sawaki et al., 2018), and contribute to spreading senescence to…”
BackgroundMethodInfluentialCellular senescence in tissue repair: every cloud has a silver lining
Yun, M. H. (2018) · The International Journal of Developmental Biology · doi:10.1387/ijdb.180081my · Cited by 41
“…the permeability of tumour capillaries (Liu and Hornsby, 2007), and the promotion of epithelial-mesenchymal transitions (EMT)(Canino et al., 2012, Coppe et al., 2008, Laberge et al., 2012), a mechanism dependent on senescence-derived IL-6 and IL-8 in vitro (Coppe et al., 2008), which can…”
BackgroundInfluentialLi, Q., Lu, H., Hu, G., Ye, Z., Zhai, D., Yan, Z., Wang, L., Xiang, A., & Lu, Z. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.194 · Cited by 40
Lee, M. Y., Leonardi, A., Begley, T. J., & Melendez, J. A. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101375 · Cited by 44
Urea-induced ROS accelerate senescence in endothelial progenitor cells
D’Apolito, M., Colia, A. L., Lasalvia, M., Capozzi, V., Falcone, M. P., Pettoello‐Mantovani, M., Brownlee, M., Maffione, A. B., & Giardino, I. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.028 · Cited by 45
Cellular senescence promotes cancer metastasis by enhancing soluble E-cadherin production
Kawaguchi, K., Komoda, K., Mikawa, R., Asai, A., & Sugimoto, M. (2021) · iScience · doi:10.1016/j.isci.2021.103022 · Cited by 43
“Although cellular senescence prevents malignant transformation, it can also promote cancer progression in a non-cell-autonomous manner through SASP (Ohtani, 2019).”
BackgroundInfluentialFrediani, E., Scavone, F., Laurenzana, A., Chillà, A., Tortora, K., Cimmino, I., Leri, M., Bucciantini, M., Mangoni, M., Fibbi, G., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17255 · Cited by 43
Responses of human embryonic stem cells and their differentiated progeny to ionizing radiation
Zou, Y., Zhang, N., Ellerby, L. M., Davalos, A. R., Zeng, X., Campisi, J., & Desprez, P.-Y. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.08.043 · Cited by 41
“However, despite staining positive for SA-Bgal, the surviving cells did not secrete IL-6, a prominent component of the SASP [28,29].”
BackgroundSelf-citationHydrogen sulfide in longevity and pathologies: Inconsistency is malodorous
Sokolov, A. S., Nekrasov, P. V., Shaposhnikov, M. V., & Moskalev, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101262 · Cited by 45
Mitochondrial Bioenergetics and Dynamics in Secretion Processes
Martínez, J., Marmisolle, I., Tarallo, D., & Quijano, C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00319 · Cited by 46
“Interestingly replicative senescent cells that present mitochondrial dysfunction (236, 237) secrete lower levels of cytokines and other mediators than oncogene induced senescent cells (20, 224).”
BackgroundInsights from In Vivo Studies of Cellular Senescence
Prieto, L. I., Graves, S. I., & Baker, D. J. (2020) · Cells · doi:10.3390/cells9040954 · Cited by 41
Benítez, S., Cordero, A., Santamaría, P. G., Redondo-Pedraza, J., Rocha, A. S., Collado-Solé, A., Jimenez, M., Sanz-Moreno, A., Yoldi, G., Santos, J. C., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.04.022 · Cited by 41
“Thus, while Rank-induced senescence in Rank localizes within the MG luminal compartment, both basal and luminal MECs show stemness features, indicating that Rank-driven paracrine senescence mechanisms such as SASP might favor stemness (Coppé et al., 2008; Malaquin et al., 2016).”
BackgroundAxitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation
Mongiardi, M. P., Radice, G., Piras, M., Stagni, V., Pacioni, S., Re, A., Putti, S., Ferrè, F., Farsetti, A., Pallini, R., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0798-2 · Cited by 43
The role of extracellular vesicles in cellular senescence
Estévez‐Souto, V., Silva‐Álvarez, S. D., & Collado, M. (2022) · FEBS Journal · doi:10.1111/febs.16585 · Cited by 52
To stay young, kill zombie cells
Scudellari, M. (2017) · Nature · doi:10.1038/550448a · Cited by 46
Senescence and Host–Pathogen Interactions
Humphreys, D., ElGhazaly, M., & Frisan, T. (2020) · Cells · doi:10.3390/cells9071747 · Cited by 46
Coppé, J., Mori, M., Pan, B., Yau, C. S. F., Wolf, D. M., Ruiz-Sáenz, A., Brunen, D., Prahallad, A., Cornelissen‐Steijger, P., Kemper, K., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0328-z · Cited by 44
Self-citationEffects of Curcumin on Aging: Molecular Mechanisms and Experimental Evidence
Bahrami, A., Montecucco, F., Carbone, F., & Sahebkar, A. (2021) · BioMed Research International · doi:10.1155/2021/8972074 · Cited by 44
“Alongside SASP, the core event in cellular senescence cell nucleus are the disturbances in DNA repair mechanisms, which determine DNA double-strand breaks senescenceassociated heterochromatin foci (SAHF), terminal cell cycle arrest with resistance to apoptosis, and loss of regeneration/resilience [37].”
BackgroundInfluentialYoon, D. S., Kim, Y. H., Lee, S., Lee, K., Park, K. H., Jang, Y., & Lee, J. W. (2014) · The FASEB Journal · doi:10.1096/fj.13-248567 · Cited by 41
The NSD2/WHSC1/MMSET methyltransferase prevents cellular senescence‐associated epigenomic remodeling
Tanaka, H., Igata, T., Etoh, K., Koga, T., Takebayashi, S., & Nakao, M. (2020) · Aging Cell · doi:10.1111/acel.13173 · Cited by 41
“…in mouse and human (Dimri et al., 1995; Jeyapalan & Sedivy, 2008) and cause tissue dysfunction at least in part through a proinflammatory program referred to as the senescence-associated secretory phenotype (SASP) or senescence-messaging secretome (Coppé et al., 2008; Kuilman & Peeper, 2009).”
BackgroundPicca, A., Calvani, R., Coelho‐Júnior, H. J., Landi, F., Bernabei, R., & Marzetti, E. (2020) · Cells · doi:10.3390/cells9030598 · Cited by 43
“Though, the cell remains metabolically active and undergoes functional changes characterized by a peculiar protein expression and secretion phenotype, known as senescence-associated secretory phenotype (SASP) [147].”
BackgroundInfluentialDifferent sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity
Inao, T., Kotani, H., Iida, Y., Kartika, I. D., Okimoto, T., Tanino, R., Shiba, E., & Harada, M. (2019) · Cancer Science · doi:10.1111/cas.14116 · Cited by 44
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100475 · Cited by 41
“Also, p53 decreases hyper-secretory phenotype also known as SASP [35] and suppresses a pro-inflammatory phenotype [36, 37].”
BackgroundBourdens, M., Jeanson, Y., Taurand, M., Juin, N., Carrière, A., Clément, F., Casteilla, L., Bulteau, A., & Planat‐Benard, V. (2019) · Scientific Reports · doi:10.1038/s41598-019-45191-2 · Cited by 52
Soluble factors influencing the neural stem cell niche in brain physiology, inflammation, and aging
Willis, C. M., Nicaise, A. M., Krzak, G., Ionescu, R.-B., Pappa, V., D’Angelo, A., Agarwal, R., Repollés-de-Dalmau, M., Peruzzotti‐Jametti, L., & Pluchino, S. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114124 · Cited by 48
“One mechanism through which senescent cells can negatively impact the local microenvironment is through the SASP, which can be triggered by DNA damage and mitochondrial dysfunction (15, 103, 104).”
BackgroundXue, H., Zhao, B., Towers, M., Liao, L., Luzete-Monteiro, E., Xu, X., Freeman, C., Peng, H., Tang, H., Havas, A. P., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00564-1 · Cited by 44
“The SASP promotes the growth of tumor cells 28 .”
Shin, H. J., Kim, I. S., Choi, S. G., Lee, K., Park, H., Shin, J., Kim, D., Beom, J., Yi, Y. Y., Gupta, D. P., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00715-x · Cited by 55
“To determine the expression of senescence markers, we compiled a list of 10 well-established SASP factors, including p21 (one of the cellular senescence markers), IL1α, IL1β, IL6, Mmp3, Mmp12, Ccl8, Cxcl1, Cxcl2, and Timp1 [46, 47].”
MethodChronic wounds – is cellular ‘reception’ at fault? Examining integrins and intracellular signalling
Widgerow, A. D. (2012) · International Wound Journal · doi:10.1111/j.1742-481x.2012.00967.x · Cited by 43
“CWF rapidly degrades exogenous GFs, decreases the production of cyclin D1, phosphorylated retinoblastoma protein RB and increases p21 (30).”
BackgroundWei, Y., Jia, S., Ding, Y., Xia, S., & Giunta, S. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.112067 · Cited by 49
“There are several drivers of inflammaging, among them: the progressive activation of innate-immunity over time; cellular senescence associated secretory phenotype (SASP) (Coppé et al., 2008; Campisi, 2005), dysbiosis of gut microbes (Claesson et al., 2011); the progressive accumulation of endogenous molecular waste (…”
James, E. L., Lane, J. A. E., Michalek, R. D., Karoly, E. D., & Parkinson, E. K. (2016) · Scientific Reports · doi:10.1038/srep38489 · Cited by 40
The Senolytic Drug JQ1 Removes Senescent Cells via Ferroptosis
Go, S., Kang, M., Kwon, S. P., Jung, M., Jeon, O. H., & Kim, B. (2021) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-021-00346-z · Cited by 43
“Notably, bleomycin-induced senescent HDFs treated with JQ1 significantly had reduced levels of p21, a frequently used senescence marker, and SASP factors IL1b, IL6, TNF alpha, and MMP9 relative to DMSOtreated bleomycin-induced senescent HDFs. JQ1 itself did not affect the mRNA levels of the SASP factors of nonsenescen…”
BackgroundInfluentialDiminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation
Künzel, S. R., Hoffmann, M., Weber, S., Künzel, K., Kämmerer, S., Günscht, M., Klapproth, E., Rausch, J. S. E., Sadek, M. S., Kolanowski, T. J., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.319425 · Cited by 41
Solomon, H., Brosh, R., Buganim, Y., & Rotter, V. (2010) · PubMed · Cited by 47
Wilmouth, J., Olabe, J., García-García, D., Lucas, C., Guiton, R., Roucher‐Boulez, F., Dufour, D., Damon‐Soubeyrand, C., Sahut‐Barnola, I., Pointud, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.add0422 · Cited by 50
Senescence of Tumor Cells in Anticancer Therapy—Beneficial and Detrimental Effects
Piskorz, W. M., & Cechowska‐Pasko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911082 · Cited by 43
“It has been proven that addition of recombinant IL-8 and IL-6 enhances the preneoplastic epithelial cells invasiveness while inhibition of these interleukins decreases it [9].”
BackgroundInfluentialRoth, I. M., Campbell, H., Cortés-Rubio, C. N., Vennin, C., Wilson, M., Wiles, A. K., Williams, G., Woolley, A. G., Timpson, P., Berridge, M. V., et al. (2016) · Oncogene · doi:10.1038/onc.2016.45 · Cited by 45
Lorenzo, E. C., Torrance, B. L., Keilich, S. R., Al‐Naggar, I. M., Harrison, A. G., Xu, M., Bartley, J. M., & Haynes, L. (2021) · Aging Cell · doi:10.1111/acel.13525 · Cited by 50
Cellular senescence in liver fibrosis: Implications for age-related chronic liver diseases
Udomsinprasert, W., Sobhonslidsuk, A., Jittikoon, J., Honsawek, S., & Chaikledkaew, U. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1992385 · Cited by 40
“Senescent cells, in turn, can alter DNA methylation signatures and also produce a wide range of cytokines and growth factors into the cell microenvironment, as well as a number of soluble and insoluble molecules, a phenomenon known as the SASP [27,28].”
BackgroundProgressive senescence programs induce intrinsic vulnerability to aging-related female breast cancer
Bai, H., Liu, X., Lin, M., Meng, Y., Tang, R., Guo, Y., Li, N., Clarke, M. F., & Cai, S. (2024) · Nature Communications · doi:10.1038/s41467-024-49106-2 · Cited by 42
“…suppresses cell proliferation, through the p53-p21 and p16 Ink4a -Rb pathways 6,7 and is accompanied by activated β -galactosidase 8 , global alteration of H3K9me3 abundance 9,10 , induction of senescence-associated secretory phenotype (SASP) factor activity 11 and disturbed immune ecosystem 12 .”
The Role of Ageing and Parenchymal Senescence on Macrophage Function and Fibrosis
Campbell, R., Docherty, M.-H., Ferenbach, D. A., & Mylonas, K. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.700790 · Cited by 45
“This is called the senescence-associated secretory phenotype (SASP) (25).”
BackgroundHigh OCT4 and Low p16 INK4A Expressions Determine In Vitro Lifespan of Mesenchymal Stem Cells
Piccinato, C. D. A., Sertie, A. L., Torres, N., Ferretti, M., & Antonioli, E. (2015) · Stem Cells International · doi:10.1155/2015/369828 · Cited by 46
Genomic regulation of senescence and innate immunity signaling in the retinal pigment epithelium
Chaum, E., Winborn, C. S., & Bhattacharya, S. (2015) · Mammalian Genome · doi:10.1007/s00335-015-9568-9 · Cited by 41
“…tissue architecture and microenvironment caused by altered gene expression , and secretion of inflammatory cytokines, growth factors, and proteases (Campisi 2003; Coppe et al. 2008; Garfinkel et al. 1994; Krtolica and Campisi 2002; Kuilman et al. 2008; Novakova et al. 2010; Ohtani and Hara 2013).”
Payea, M. J., Dar, S. A., Anerillas, C., Martindale, J. L., Belair, C., Munk, R. B., Malla, S., Fan, J., Piao, Y., Yang, X., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.10.003 · Cited by 47
An Overview of the Current State of Cell Viability Assessment Methods Using OECD Classification
Madorran, E., Ambrož, M., Knez, J., & Sobočan, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010220 · Cited by 59
Gene regulatory network underlying the immortalization of epithelial cells
Méndez-López, L. F., Dávila-Velderrain, J., Domínguez‐Hüttinger, E., Enríquez-Olguín, C., Martínez‐García, J. C., & Alvarez-Buylla, E. R. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0393-5 · Cited by 43
“Indeed, several pro-inflammatory cytokines such as TFG-β [80] and IL-6 [81], some of which are produced by senescent cells [82], have shown to be strong inducers of EMT.”
Role of senescence in the chronic health consequences of COVID-19
Wissler Gerdes, E. O., Vanichkachorn, G., Verdoorn, B. P., Hanson, G. J., Joshi, A. Y., Murad, M. H., Rizza, S. A., Hurt, R. T., Tchkonia, T., & Kirkland, J. L. (2022) · Translational Research · doi:10.1016/j.trsl.2021.10.003 · Cited by 38
Senescent cells enhance newt limb regeneration by promoting muscle dedifferentiation
Walters, H. E., Troyanovskiy, K. E., Graf, A. M., & Yun, M. H. (2023) · Aging Cell · doi:10.1111/acel.13826 · Cited by 39
Noncoding RNAs Controlling Telomere Homeostasis in Senescence and Aging
Rossi, M. S., & Gorospe, M. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.01.010 · Cited by 51
CXCL5‐CXCR2 signaling is a senescence‐associated secretory phenotype in preimplantation embryos
Kawagoe, Y., Kawashima, I., Sato, Y., Okamoto, N., Matsubara, K., & Kawamura, K. (2020) · Aging Cell · doi:10.1111/acel.13240 · Cited by 39
“We found CXCL5 treatment of young embryos increased the expression of four aging biomarkers (Coppe et al., 2008; Goldstein, Moerman, Fujii, & Sobel, 1994; Kuilman et al., 2008), resulting in impairment of embryo implantation.”
BackgroundThe Role of cGAS-STING in Age-Related Diseases from Mechanisms to Therapies
Zheng, W., Feng, D., Xiong, X., Liao, X., Wang, S., Xu, H., Le, W., Wei, Q., & Yang, L. (2023) · Aging and Disease · doi:10.14336/ad.2023.0117 · Cited by 50
“However, SASP is a doubleedged sword; it can also promote tumorigenesis by inducing the proliferation, transformation, invasiveness, and metastasis of epithelial cells [23, 24].”
BackgroundShould we treat aging as a disease? The consequences and dangers of miscategorisation
Faragher, R. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00171 · Cited by 44
“However, cellular senescence is typically associated with the heavily upregulated secretion of proinflammatory factors and other changes which have the potential to produce degenerative effects (Coppé et al., 2008; Burton et al., 2009; Kipling et al., 2009).”
BackgroundNikolakis, G. D., Makrantonaki, E., & Zouboulis, C. C. (2013) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2013-0018 · Cited by 46
Jeon, H.-Y., Ham, S. W., Kim, J.-K., Jin, X. J., Lee, S. Y., Shin, Y. J., Choi, C., Sa, J. K., Kim, S. H., Chun, T., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0282-0 · Cited by 39
“The SASP includes a variety of cytokines and chemokines that regulate tumor cell proliferation, invasion, migration, and inflammatory cell recruitment [36, 41].”
BackgroundSakaki, M., Ebihara, Y., Okamura, K., Nakabayashi, K., Igarashi, A., Matsumoto, K., Hata, K., Kobayashi, Y., & Maehara, K. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171431 · Cited by 39
Senescent cells in human adipose tissue: A cross‐sectional study
Espinosa De Ycaza, A. E., Søndergaard, E., Morgan‐Bathke, M., Carranza Leon, B. G., Lytle, K. A., Ramos, P., Kirkland, J. L., Tchkonia, T., & Jensen, M. D. (2021) · Obesity · doi:10.1002/oby.23202 · Cited by 39
“function of senescent cells varies among tissues and cell types (4), and many cell types can undergo senescence.”
BackgroundFOXQ1 regulates senescence-associated inflammation via activation of SIRT1 expression
Wang, P., Lv, C., Zhang, T., Liu, J., Yang, J., Guan, F., & Hong, T. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.340 · Cited by 43
“There is mounting evidence that senescent cells, which often persist in vivo, can promote tumor progression in addition to other age-related pathologies via the senescence-associated secretory phenotype (SASP).(7,8) Senescent cells can secret numerous kinds of pro-inflammatory cytokines, chemokines, growth factors and…”
BackgroundInfluentialA Sensitive Method to Quantify Senescent Cancer Cells
Cahu, J., & Sola, B. (2013) · Journal of Visualized Experiments · doi:10.3791/50494 · Cited by 39
DPY30 regulates pathways in cellular senescence through ID protein expression
Simboeck, E., Gutiérrez, A., Cozzuto, L., Beringer, M., Caizzi, L., Keyes, W. M., & Croce, L. D. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.159 · Cited by 39
“Several cytokines and chemokines are known to be highly expressed and secreted in OIS and lead to the so-called SASP (Coppe et al , 2008).”
InfluentialSasaki, S., Baba, T., Muranaka, H., Tanabe, Y., Takahashi, C., Matsugo, S., & Mukaida, N. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0845 · Cited by 46
“NF-kB activation can be observed in cellular senescence provoked by p53 activation(31), but 5-FU failed to increase senescence-associated b-galactosidase staining, a characteristic feature of cellular senescence, in 4T1 and TS/A cells (Supplementary Fig.”
BackgroundMaxwell, F., McGlynn, L. M., Muir, H. C., Talwar, D., Benzeval, M., Robertson, T., Roxburgh, C. S., McMillan, D. C., Horgan, P. G., & Shiels, P. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3271 · Cited by 39
“Recent evidence indicates that senescent cells secrete a multitude of signaling factors, termed the "senescence-associated secretory phenotype" (SASP; ref.”
BackgroundInfluentialFranzin, R., Stasi, A., Ranieri, E., Netti, G. S., Cantaluppi, V., Gesualdo, L., Stallone, G., & Castellano, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.630419 · Cited by 41
“As described previously, when these cells become senescent, they are metabolically active and have a distinct secretome termed SASP (Coppé et al., 2008).”
BackgroundA guide to senolytic intervention in neurodegenerative disease
Lee, S., Wang, E. Y., Steinberg, A. B., Walton, C. C., Chinta, S. J., & Andersen, J. K. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111585 · Cited by 39
Marthandan, S., Menzel, U., Priebe, S., Groth, M., Guthke, R., Platzer, M., Hemmerich, P., Kaether, C., & Diekmann, S. (2016) · Biological Research · doi:10.1186/s40659-016-0095-2 · Cited by 39
“Our results point to a heterogeneous regulation of SASP at the transcript level.”
BackgroundResultInfluentialWang, S., Li, B., Li, J., Cai, Z., Hugo, C., Sun, Y., Qian, L., TCW, J., Chui, H. C., Dikeman, D., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00802-7 · Cited by 39
“Senescent cells secrete a range of inflammatory mediators, collectively known as the senescence-associated secretory phenotype (SASP) [4–6] that contribute to AD pathology.”
Self-citationMorales-Valencia, J., Lau, L., Martí-Nin, T., Özerdem, U., & David, G. (2022) · Oncogene · doi:10.1038/s41388-022-02433-4 · Cited by 42
Cellular senescence and the blood–brain barrier: Implications for aging and age-related diseases
Knopp, R. C., Erickson, M. A., Rhea, E. M., Reed, M. J., & Banks, W. A. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231157917 · Cited by 48
Myeloma cells can corrupt senescent mesenchymal stromal cells and impair their anti-tumor activity
Özcan, S., Alessio, N., Acar, M. B., Toprak, G., Gönen, Z. B., Peluso, G., & Galderisi, U. (2015) · Oncotarget · doi:10.18632/oncotarget.5430 · Cited by 43
Insulin-like growth factor binding protein-6 delays replicative senescence of human fibroblasts
Micutkova, L., Diener, T., Li, C., Rogowska-Wrzesinska, A., Mueck, C., Huetter, E., Weinberger, B., Grubeck-Loebenstein, B., Roepstorff, P., Zeng, R., et al. (2011) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2011.07.005 · Cited by 39
Pitiyage, G. N., Lim, K. P., Gemenitzidis, E., Teh, M., Waseem, A., Prime, S. S., Tilakaratne, W. M., Fortune, F., & Parkinson, E. K. (2012) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2012.01129.x · Cited by 41
Are aging biomarkers clinically relevant in oncogeriatrics?
Falandry, C., Gilson, É., & Rudolph, K. L. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.08.004 · Cited by 44
“[6,49]), and (5) DNA damge induced changes in tissue composition, especially in the mmune system: decrease production of naïve lymphocytes ith a concomitant increase myeloid cell lineages (Fig.”
BackgroundKim, Y. H., & Park, T. J. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.295 · Cited by 44
G Protein-Coupled Receptor Systems as Crucial Regulators of DNA Damage Response Processes
Leysen, H., van Gastel, J., Hendrickx, J. O., Santos‐Otte, P., Martin, B., & Maudsley, S. R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102919 · Cited by 39
“SASP responses, like cell cycle arrest events, can also be dependent on protracted DNA damage signaling [143], caused by the feed-forward loops that can be generated between DDR signaling and ROS attack [144].”
BackgroundInfluentialKokal, M., Mirzakhani, K., Pungsrinont, T., & Baniahmad, A. (2020) · Cancers · doi:10.3390/cancers12071833 · Cited by 46
Miller, K. N., Li, B., Pierce-Hoffman, H. R., Patel, S., Lei, X., Rajesh, A., Teneche, M. G., Havas, A. P., Gandhi, A., Macip, C. C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57229-3 · Cited by 229
“It has previously been reported that p53 suppresses the SASP 2,61 , consistent with the observation that p53 activity declines in senescence after cell cycle exit, while SASP increases 62 — but the mechanism of SASP suppression by p53 has been unclear.”
Senescence Inducer Shikonin ROS-Dependently Suppressed Lung Cancer Progression
Zheng, H., Huang, Q., Huang, S., Yang, X., Zhu, T., Wang, W., Wang, H., He, S., Ji, L., Wang, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00519 · Cited by 40
“Other studies also revealed that senescence stimulate immunosurveillance to eliminate tumor cells (Coppé et al., 2009; Rakhra et al., 2010), therefore, the effects of SHK on immune cells such as natural killer cells, T, B, and macrophages need to be further determined.”
BackgroundAnti‐inflammaging effects of human alpha‐1 antitrypsin
Yuan, Y., DiCiaccio, B., Li, Y., Elshikha, A. S., Titov, D., Brenner, B. R., Seifer, L., Pan, H., Karic, N., Akbar, M. A., et al. (2017) · Aging Cell · doi:10.1111/acel.12694 · Cited by 38
“Following irradiation, HCA2 cells were cultured for 7 days to allow completion of senescence (Coppe et al., 2008).”
BackgroundMethodInfluentialCellular senescence as a therapeutic target to improve renal transplantation outcome
van Willigenburg, H., de Keizer, P. L. J., & de Bruin, R. W. F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.015 · Cited by 38
“MMP-1, −3, −10) and growth factors [26,27].”
Role of Senescent Renal Cells in Pathophysiology of Diabetic Kidney Disease
Wiley, C. D. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01314-y · Cited by 39
Social selection and the evolution of cooperative groups: The example of the cellular slime moulds
Nanjundiah, V., & Sathe, S. (2011) · Integrative Biology · doi:10.1039/c0ib00115e · Cited by 41
Bcl-xL as a Modulator of Senescence and Aging
Mas‐Bargues, C., Borrás, C., & Viña, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041527 · Cited by 41
“Proliferation (Ki67, BrdU assay) Absent [15,16] Cell cycle inhibitors (p21CIP1, p16INK4a) Increased [17–19] DNA damage (p53, γH2AX foci, TAF, SAHF, SADF) Increased [20–25] SA-β-gal activity Increased [26–28] Lamin B1 Decreased [29] Nuclear exclusion of HMGB1 Present [30] SASP factors (IL-1, IL-6, IL-8, PAI-1, MMPs) Pr…”
BackgroundZhang, H., Xu, Q., Jiang, Z., Sun, R., Wang, Q., Liu, S., Luan, X., Campisi, J., Kirkland, J. L., Zhang, W., et al. (2025) · Advanced Science · doi:10.1002/advs.202412950 · Cited by 56
Self-citationProgrammed cell senescence: role of IL-6 in the pituitary
Sapochnik, M., Fuertes, M., & ARZT, E. S. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0026 · Cited by 44
Pòcsfalvi, G., Votta, G., Vincenzo, A. D., Fiume, I., Raj, D. A. A., Marra, G., Stoppelli, M. P., & Iaccarino, I. (2011) · Journal of Proteome Research · doi:10.1021/pr200584y · Cited by 40
Diniz, B. S., Mulsant, B. H., Reynolds, C. F., Blumberger, D. M., Karp, J. F., Butters, M. A., Mendes-Silva, A. P., Vieira, E. L., Tseng, G., & Lenze, E. J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.19678 · Cited by 39
Liu, J., Xu, K., Chase, M., Ji, Y., Logan, J. K., & Buchsbaum, R. J. (2012) · Journal of Cell Science · doi:10.1242/jcs.089466 · Cited by 40
“Senescent stromal cells can increase multiple neoplastic properties of associated epithelial cells, including growth, survival, epithelial–mesenchymal transition (EMT) and invasiveness (Krtolica et al., 2001; Coppe et al., 2008).”
BackgroundLee, H. C., Kang, D., Han, N., Lee, Y., Hwang, H. J., Lee, S.-B., You, J. S., Min, B. S., Park, H. J., Ko, Y., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0467-6 · Cited by 39
Blagosklonny, M. V. (2012) · Oncotarget · doi:10.18632/oncotarget.890 · Cited by 39
The human immunosenescence phenotype: does it exist?
Pawelec, G. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00810-3 · Cited by 43
Cellular Senescence Variation by Metabolic and Epigenomic Remodeling
Nakao, M., Tanaka, H., & Koga, T. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.08.009 · Cited by 41
Effects of senescence on the tumour microenvironment and response to therapy
Reynolds, L. E., Maallin, S., Haston, S., Martínez-Barberá, J. P., Hodivala‐Dilke, K., & Pedrosa, A. (2023) · FEBS Journal · doi:10.1111/febs.16984 · Cited by 45
“The SASP can stimulate immunosurveillance mechanisms by directing the immune system to enhance anti-cancer responses [8,11].”
Al‐Khalaf, H. H., Ghebeh, H., Inass, R., & Aboussekhra, A. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00359-18 · Cited by 41
“Similar results were previously shown for normal human prostate epithelial cells (7), indicating that both epithelial cells and fibroblasts can senesce with striking similarities but with different sensitivities.”
Result
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.